Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of BI 425809 in Healthy Volunteers
NCT02337283Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2015
- Primary completion
- Nov 2015
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of iclepertin (7 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Percentage of Subjects With Drug Related Adverse Events up to 25 days, Area Under the Concentration-time Curve from 0 to Last Quantifiable Data Point up to 96 hours and 1 more. Started Jan 2015; status: completed.
02
Drugs
iclepertin
Beyond the preview
Go deeper on NCT02337283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02337283.